Evidence map›Paper›PMID 41834023›Full record

ArticleScientific reports2026

Dynamic changes of monocytes-related immune activation in people with HIV switching to long-acting injectable cabotegravir plus rilpivirine.

Maria Antonella Zingaropoli, Mariasilvia Guardiani, Anna Carraro, Eeva Tortellini, Federica Dominelli, Michele Antonacci, Cosmo Del Borgo, Raffaella Marocco, Giulia Mancarella, Lorenzo Ansaldo and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Maria Antonella ZingaropoliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy. mariaantonella.zingaropoli@uniroma1.it.
Mariasilvia GuardianiDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Anna CarraroDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Eeva TortelliniDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Federica DominelliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Michele AntonacciDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Cosmo Del BorgoInfectious Diseases Unit, Sapienza University of Rome, SM Goretti Hospital, Latina, Italy.
Raffaella MaroccoInfectious Diseases Unit, Sapienza University of Rome, SM Goretti Hospital, Latina, Italy.
Giulia MancarellaDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Lorenzo AnsaldoInfectious Diseases Unit, Sapienza University of Rome, SM Goretti Hospital, Latina, Italy.
Piergiorgio PaceInfectious Diseases Unit, Sapienza University of Rome, SM Goretti Hospital, Latina, Italy.
Livia BrescianiDepartment of Neurosciences, Mental Health, and Sense Organs, Sapienza University of Rome, NESMOS, Rome, Italy.
Serena VitaDepartment of Neurosciences, Mental Health, and Sense Organs, Sapienza University of Rome, NESMOS, Rome, Italy.
Fabio MengoniDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Roberta CampagnaDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Ombretta TurrizianiMicrobiology and Virology Unit, University Hospital Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Maria Rosa CiardiDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Claudio Mastroianni MastroianniDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Miriam LichtnerMicrobiology and Virology Unit, University Hospital Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.

Funding

Project Sapienza University fund n° B83C24007070005
6 · The paper itself

Abstract

The aim of this study was to examine the dynamic changes in monocyte/macrophage- and dendritic cell (DC)-related immune activation in people with HIV (PWH) before switching to long-acting (LA) injectable cabotegravir (CAB) plus rilpivirine (RPV) (T0), after six (T6m) and twelve months (T12m). A total of 30 aviremic PWH switching to LA CAB plus RPV, and 32 healthy donors (HDs) were enrolled. At each time point, in comparison to HDs, PWH exhibited higher classical and intermediate monocyte counts and lower slanDC and pDC counts. Compared to HDs, in PWH non-classical monocyte counts were higher only at T0. PWH exhibited elevated sCD163 and sCD14 plasmatic levels at each time point, in comparison to HDs. No virological failure was observed. At T12m, no differences in the total cell-associated HIV-1 DNA levels compared to T0 were found. The longitudinal evaluation showed a significant reduction in non-classical and intermediate monocyte counts at T12m compared to T0 and an increase in classical monocyte and pDC counts. Furthermore, a reduction in sCD14 plasma levels was observed. The constant drug concentrations provided by CAB plus RPV injections appear to be effective for a sustained and deep virological suppression that may reduce monocyte/macrophage activation in PWH.

Indexed as

Anti-HIV AgentsHIV InfectionsMonocytesPyridonesRilpivirineAdultDendritic CellsDiketopiperazinesFemaleHIV-1HumansMacrophagesMaleMiddle AgedAnti-HIV AgentscabotegravirDiketopiperazinesPyridonesRilpivirineCabotegravirDendritic cells, HIV-DNA, flow-cytometryLong-acting therapyMonocytesRilpivirineSCD14SCD163

Identifiers

PMID41834023
PMCPMC13121530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.